Skip to main content

Pimobendan

ADVERTISEMENT
Identification
Molecular formula
C19H18N4O2S
CAS number
74150-27-9
IUPAC name
4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide
State
State

At room temperature, Pimobendan is a solid.

Melting point (Celsius)
216.00
Melting point (Kelvin)
489.20
Boiling point (Celsius)
537.70
Boiling point (Kelvin)
810.90
General information
Molecular weight
334.44g/mol
Molar mass
334.3960g/mol
Density
1.3980g/cm3
Appearence

Pimobendan appears as a white to off-white crystalline powder. It is generally available in tablet form for pharmaceutical use.

Comment on solubility

Solubility of 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide

The solubility of the compound 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide (C19H18N4O2S) can be influenced by various factors, primarily due to its complex structure. Here are some important points to consider regarding its solubility:

  • Polar and Nonpolar Interaction: The presence of both polar and nonpolar functional groups in this compound suggests variable solubility in different solvents.
  • Solvent Considerations: It may exhibit higher solubility in polar organic solvents like dimethyl sulfoxide (DMSO) or ethanol, while being *less soluble in nonpolar solvents* due to its substantial molecular weight and hydrophilic sulfonamide group.
  • Temperature Effects: Solubility can also be temperature-dependent; generally, as the temperature increases, solubility tends to improve for many compounds.
  • pH Dependency: Changes in pH can affect the ionization of the sulfonamide functional group, potentially increasing the compound's solubility in aqueous solutions.

Overall, while specific solubility data may be limited, its structural features suggest a propensity for moderate solubility in polar solvents, influenced by environmental conditions such as temperature and pH. Further empirical studies would help clarify its solubility profile in various media.

Interesting facts

Interesting Facts about 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide

This compound, known for its complex structure and intriguing applications, presents a fascinating area of study within medicinal chemistry. Here are some compelling points regarding this compound:

  • Structure Highlights: The compound features a purine base, which is essential in biochemistry as purines are fundamental components of nucleotides. This structural aspect suggests potential interactions with nucleic acids.

  • Pharmacological Potential: Compounds with sulfonamide groups have been recognized for their antibacterial properties. This particular molecule's unique substituents may enhance its pharmacological profile, making it a candidate for drug development.

  • Versatile Applications: Due to its complex functionality, this compound could be explored in various therapeutic areas such as oncology, cardiovascular diseases, and even neurological disorders. Research into similar compounds has opened doors to innovative treatments.

  • Research Significance: The study of purine derivatives has contributed significantly to our understanding of many biological processes. The ability to modify the purine structure can lead to targeted therapeutic strategies, enhancing efficacy while reducing side effects.

  • Cyclohexylmethoxy Group: The presence of the cyclohexylmethoxy moiety may impart unique steric and electronic characteristics, potentially impacting the compound's bioactivity and interaction with biological targets. The cyclic structure may also influence its pharmacokinetics.

As scientists continue to investigate compounds like 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide, the potential for breakthroughs in drug discovery remains promising. The fields of organic and medicinal chemistry are poised for exciting developments as these complex molecules are studied further.

Synonyms
nu6102
444722-95-6
NU-6102
O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE
NU 6102
4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide
CHEMBL319467
X5J53DR704
4-((6-(Cyclohexylmethoxy)-1H-purin-2-yl)amino)benzenesulfonamide
4-((6-(cyclohexylmethoxy)-9H-purin-2-yl)amino)benzenesulfonamide
4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide
4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide
4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide
4SP
1h1s
Cdk1/2 Inhibitor II, NU6102
4eok
4eor
2c6o
2iw8
2iw9
UNII-X5J53DR704
BDBM5544
O(6)-cyclohexylmethoxy-2-(4'-sulfamoylanilino)purine
SCHEMBL2170816
SCHEMBL12589612
DTXSID70274438
NU610
BCP31257
USA72295
BDBM50235342
HSCI1_000264
AKOS040749056
DB07126
NCGC00346950-01
NCGC00346950-03
HY-15569
MS-26859
NU-6102; NU 6102
CS-0007087
NS00069512
G13513
K00275
O6-Cyclohexylmethyl-2-(4-sulfamoylanilino)purine
6-Cyclohexylmethoxy-2-(4 -sulfamoylanilino)purine
Q27096041
4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzene-1-sulfonamide
BENZENESULFONAMIDE, 4-((6-(CYCLOHEXYLMETHOXY)-1H-PURIN-2-YL)AMINO)-
BENZENESULFONAMIDE, 4-((6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL)AMINO)-